RPR Planning U.S. Filing For Novartis' Revasc Following Licensing Deal
Executive Summary
Rhone-Poulenc Rorer is preparing for U.S. filing of Novartis' Revasc (desirudin) after gaining rights to the anti-thrombolytic agent for the prevention of deep-vein thrombosis after knee and hip replacement surgery.